Indication
Pheochromocytoma/Paragangliomas
1 clinical trial
2 products
1 drug
Clinical trial
Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersStatus: Not yet recruiting, Estimated PCD: 2029-01-01
Product
[212Pb]VMT-alpha-NETProduct
[203Pb]VMT-alpha-NETDrug
68Ga-DOTATATE